Claims for Patent: 8,604,064
✉ Email this page to a colleague
Summary for Patent: 8,604,064
Title: | Process for the preparation of roflumilast |
Abstract: | A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight. |
Inventor(s): | Kohl; Bernhard (Constance, DE), Mueller; Bernd (Constance, DE), Palosch; Walter (Rielasingen, DE) |
Assignee: | Takeda GmbH (Constance, DE) |
Application Number: | 13/860,248 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,604,064 |
Patent Claims: |
1. A method for the treatment of an acute or chronic airway disorder comprising: administering to a patient suffering from an acute or chronic airway disorder, a
therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less
than 0.1% by weight.
2. The method of claim 1, wherein said roflumilast has a purity of greater than or equal to 99.8% by weight. 3. The method of claim 1, wherein said N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight. 4. A method for the treatment of an acute or chronic airway disorder comprising: administering to a patient suffering from an acute or chronic airway disorder, a therapeutically effective amount of a pharmaceutical composition, comprising: roflumilast having a purity of greater than or equal to 99% by weight; N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight; and pharmaceutically acceptable auxiliaries and/or excipients. 5. The method of claim 4, wherein said roflumilast has a purity of greater than or equal to 99.8% by weight. 6. The method of claim 4, wherein said N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight. 7. A method for the treatment of an acute or chronic airway disorder comprising: administering to a patient suffering from an acute or chronic airway disorder, a therapeutically effective amount of a pharmaceutical dosage form, comprising: roflumilast having a purity of greater than or equal to 99% by weight; N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight; and pharmaceutically acceptable auxiliaries and/or excipients. 8. The method of claim 7, wherein said roflumilast has a purity of greater than or equal to 99.8% by weight. 9. The method of claim 7, wherein said N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight. 10. The method of claim 7, wherein said pharmaceutical dosage form is selected from the group consisting of tablets, coated tablets, capsules, caplets, suppositories, emulsions, suspensions, gels and solutions. 11. The method of claim 7, wherein said pharmaceutical dosage form includes from between 0.1% and 95% roflumilast. 12. The method of claim 7, wherein the pharmaceutical dosage form is an oral dosage form. 13. The method of claim 7, wherein the pharmaceutical dosage form contains from 0.05 mg to 2.5 mg of roflumilast. 14. The method of claim 13, wherein the pharmaceutical dosage form contains from 0.1 to 0.5 mg of roflumilast. 15. The method of claim 14, wherein the pharmaceutical dosage form contains 0.25 mg of roflumilast. 16. The method of claim 14, wherein the pharmaceutical dosage form contains 0.5 mg of roflumilast. 17. A method for the treatment of an acute or chronic airway disorder comprising: administering to a patient suffering from an acute or chronic airway disorder, a therapeutically effective amount of a pharmaceutical tablet, comprising: 0.5 mg of roflumilast having a purity of greater than or equal to 99% by weight; N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount less than 0.1% by weight; and pharmaceutically acceptable auxiliaries and/or excipients. 18. The method of claim 17, wherein said roflumilast has a purity of greater than or equal to 99.8% by weight. 19. The method of claim 17, wherein said N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight. 20. The method of claim 1, wherein said disorder is selected from the group consisting of asthma, bronchitis, allergic rhinitis, emphysema and chronic obstructive pulmonary disease. 21. The method of claim 4, wherein said disorder is selected from the group consisting of asthma, bronchitis, allergic rhinitis, emphysema and chronic obstructive pulmonary disease. 22. The method of claim 7, wherein said disorder is selected from the group consisting of asthma, bronchitis, allergic rhinitis, emphysema and chronic obstructive pulmonary disease. 23. The method of claim 17, wherein said disorder is selected from the group consisting of asthma, bronchitis, allergic rhinitis, emphysema and chronic obstructive pulmonary disease. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.